Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
John F. Crowley, President and CEO of the…
“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the United States and the cornerstone of America’s…
CSBA Letter to Congressional Leadership on Most…
CSBA Letter to Congressional Leadership on…
The Council of State Bioscience Associations (CSBA) is a coalition of independent state and territory-based non-profit trade associations, each of which advocates for public policies that support responsible development and delivery of innovative…
All Letters, Testimony & Comments
  • Show All
Search
Results
April 29, 2021
The Biotechnology Innovation Organization (BIO) is pleased to respond to the U.S. Department of Agriculture’s (USDA) Request for Comments: Executive Order on Tackling the Climate Crisis at Home and Abroad as USDA develops a Climate-Smart…
April 29, 2021
The farmers, ranchers, agricultural retailers, cooperatives, researchers, scientists, seed producers, and technology developers represented by the organizations signed below appreciate the opportunity to provide input for the United States…
April 27, 2021
On behalf of the Biotechnology Innovation Organization (BIO), the global industry organization representing the biotechnology industry, I want to express support for House Bill 1091, which recently passed the Washington Legislature. BIO member…
April 23, 2021
We write to you in strong support of President Biden’s nomination of Jewel Bronaugh, PhD to serve as Deputy Secretary of Agriculture and ask that you quickly approve her nomination. As leaders of the nation’s food and agricultural organizations, we…
April 9, 2021
The Biotechnology Innovation Organization (BIO) submitted the below comments to the National Institute of Standards and Technology on proposed revisions to regulations that would further the Return on Investment (ROI) Initiative for Unleashing…
April 6, 2021
On Tuesday, April 6th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s January 2021 draft industry guidance on “Human Gene Therapy for Neurodegenerative Diseases.” In its comments, BIO stated that while the guidance covers…
April 2, 2021
Dear Secretary Buttigieg, National Climate Advisor McCarthy, and Director Deese: The undersigned organizations, representing aviation industry stakeholders including passenger and cargo carriers, business and general aviation, aircraft and engine…
March 26, 2021
On Friday, March 26th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s public meeting announcement titled, “Best Practices for Development and Application of Disease Progression Models.” BIO appreciates that FDA is seeking…
March 26, 2021
The Biotechnology Innovation Organization is delighted to support the Inventor Diversity for Economic Advancement Act of 2021 and urge swift enactment of this important measure.